CN108349962A - 取代的吡唑和吡咯化合物以及使用其用于抑制翻译起始和治疗与其相关的疾病和病症的方法 - Google Patents

取代的吡唑和吡咯化合物以及使用其用于抑制翻译起始和治疗与其相关的疾病和病症的方法 Download PDF

Info

Publication number
CN108349962A
CN108349962A CN201680045318.9A CN201680045318A CN108349962A CN 108349962 A CN108349962 A CN 108349962A CN 201680045318 A CN201680045318 A CN 201680045318A CN 108349962 A CN108349962 A CN 108349962A
Authority
CN
China
Prior art keywords
optionally substituted
alkyl
fluoroalkyl
independently selected
bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680045318.9A
Other languages
English (en)
Chinese (zh)
Inventor
M.A.西迪基
S.西布拉特
M.德里
L.康斯坦蒂诺-福盖特
C.格兰德-迈特雷
X.郭
S.斯里瓦斯塔瓦
G.W.希普斯
A.B.库珀
N.布鲁诺-拉图尔
V.L.李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bantam Pharmaceutical LLC
Original Assignee
Bantam Pharmaceutical LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bantam Pharmaceutical LLC filed Critical Bantam Pharmaceutical LLC
Publication of CN108349962A publication Critical patent/CN108349962A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680045318.9A 2015-06-01 2016-06-01 取代的吡唑和吡咯化合物以及使用其用于抑制翻译起始和治疗与其相关的疾病和病症的方法 Pending CN108349962A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562169376P 2015-06-01 2015-06-01
US62/169,376 2015-06-01
PCT/US2016/035288 WO2016196644A1 (en) 2015-06-01 2016-06-01 Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto

Publications (1)

Publication Number Publication Date
CN108349962A true CN108349962A (zh) 2018-07-31

Family

ID=56118071

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680045318.9A Pending CN108349962A (zh) 2015-06-01 2016-06-01 取代的吡唑和吡咯化合物以及使用其用于抑制翻译起始和治疗与其相关的疾病和病症的方法

Country Status (9)

Country Link
US (2) US10537558B2 (https=)
EP (1) EP3303332A1 (https=)
JP (1) JP6707630B2 (https=)
CN (1) CN108349962A (https=)
BR (1) BR112017025851A2 (https=)
CA (1) CA3025492A1 (https=)
IL (1) IL255898A (https=)
MX (1) MX2017015456A (https=)
WO (1) WO2016196644A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110603254A (zh) * 2016-11-30 2019-12-20 班塔姆制药有限责任公司 被取代的吡唑化合物以及使用其治疗过度增生性疾病的方法
CN110769823A (zh) * 2016-11-30 2020-02-07 班塔姆制药有限责任公司 使用被取代的吡唑和吡咯化合物以及治疗过度增生性疾病的方法
CN110950848A (zh) * 2018-09-27 2020-04-03 徐诺药业 新型氨基吡唑类衍生物的合成与应用
CN114867724A (zh) * 2019-05-31 2022-08-05 班塔姆制药有限责任公司 用于制备噻唑基吡唑甲酸及其中间体的方法
CN115515685A (zh) * 2020-03-03 2022-12-23 皮克医疗公司 Eif4e抑制剂及其用途

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017015456A (es) 2015-06-01 2018-11-29 Bantam Pharmaceutical Llc Compuestos de pirazol y pirrol sustituidos y metodos para su uso por inhibición de iniciación de traducción y tratamiento de enfermedades y trastornos relacionados con ellos.
JP7301042B2 (ja) 2018-03-30 2023-06-30 住友化学株式会社 複素環化合物及びそれを含有する有害節足動物防除組成物
BR112020024794A2 (pt) * 2018-06-07 2021-03-02 Bantam Pharmaceutical, Llc métodos de tratamento de câncer com compostos de pirrol e pirazol substituídos e diagnóstico de câncer suscetível a tratamento com compostos de pirrol e pirazol substituídos
WO2020051424A1 (en) 2018-09-07 2020-03-12 Pic Therapeutics Eif4e inhibitors and uses thereof
CN114502551B (zh) 2019-11-01 2023-08-22 优迈特株式会社 含氟嘧啶化合物及其制备方法
CA3229560A1 (en) 2021-08-25 2023-03-02 Christopher L. Vandeusen Eif4e inhibitors and uses thereof
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6468979B1 (en) * 1998-07-30 2002-10-22 Zambon Group S.P.A. Erythromycin derivatives with antibiotic activity
US20030220356A1 (en) * 2002-04-04 2003-11-27 Prabha Ibrahim ABCA-1 elevating compounds
WO2004094395A2 (en) * 2003-04-18 2004-11-04 Merck & Co., Inc. Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
WO2007138110A2 (en) * 2006-06-01 2007-12-06 Devgen N.V. Compounds that interact with ion channels, in particular with ion channels from the kv family
WO2009027393A2 (en) * 2007-08-27 2009-03-05 Basf Se Pyrazole compounds for controlling invertebrate pests
EP2264017A1 (en) * 2008-04-04 2010-12-22 Takeda Pharmaceutical Company Limited Heterocyclic derivative and use thereof
WO2014066304A1 (en) * 2012-10-22 2014-05-01 Egenix, Inc. Compositions and methods for treating or preventing diseases or disorders associated with misregulated eif4e

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342851A (en) * 1992-10-07 1994-08-30 Mcneil-Ppc, Inc. Substituted thiazole derivatives useful as platelet aggregation inhibitors
EP1104759B1 (en) * 1999-12-03 2003-10-22 Pfizer Products Inc. Heteroaryl phenyl pyrazole compounds as anti-inflammatory/analgesic agents
CN100387594C (zh) 2003-04-03 2008-05-14 麦克公司 二芳基取代的吡唑类代谢型谷氨酸受体-5调节剂
WO2008121861A2 (en) 2007-03-28 2008-10-09 Xenon Pharmaceuticals Inc. Pyrazole and pyrrole compounds useful in treating iron disorders
KR101608259B1 (ko) 2008-04-28 2016-04-01 교린 세이야꾸 가부시키 가이샤 시클로펜틸아크릴산아미드 유도체
WO2012080729A2 (en) * 2010-12-14 2012-06-21 Electrophoretics Limited CASEIN KINASE 1δ (CK1δ) INHIBITORS
WO2015144290A1 (en) 2014-03-27 2015-10-01 Merck Patent Gmbh Pyridyl piperidines
CN108040481B (zh) 2015-04-24 2020-10-30 先正达参股股份有限公司 具有硫取代的五元环杂环的杀有害生物活性多环衍生物
MX2017015456A (es) 2015-06-01 2018-11-29 Bantam Pharmaceutical Llc Compuestos de pirazol y pirrol sustituidos y metodos para su uso por inhibición de iniciación de traducción y tratamiento de enfermedades y trastornos relacionados con ellos.

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6468979B1 (en) * 1998-07-30 2002-10-22 Zambon Group S.P.A. Erythromycin derivatives with antibiotic activity
US20030220356A1 (en) * 2002-04-04 2003-11-27 Prabha Ibrahim ABCA-1 elevating compounds
WO2004094395A2 (en) * 2003-04-18 2004-11-04 Merck & Co., Inc. Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
WO2007138110A2 (en) * 2006-06-01 2007-12-06 Devgen N.V. Compounds that interact with ion channels, in particular with ion channels from the kv family
WO2009027393A2 (en) * 2007-08-27 2009-03-05 Basf Se Pyrazole compounds for controlling invertebrate pests
EP2264017A1 (en) * 2008-04-04 2010-12-22 Takeda Pharmaceutical Company Limited Heterocyclic derivative and use thereof
WO2014066304A1 (en) * 2012-10-22 2014-05-01 Egenix, Inc. Compositions and methods for treating or preventing diseases or disorders associated with misregulated eif4e

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SAMIA M. RIDA，等: "Synthesis of Novel Benzofuran and Related Benzimidazole Derivatives for Evaluation of In Vitro Anti-HIV-1, Anticancer and Antimicrobial Activities", 《ARCH PHARM RES》 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110603254A (zh) * 2016-11-30 2019-12-20 班塔姆制药有限责任公司 被取代的吡唑化合物以及使用其治疗过度增生性疾病的方法
CN110769823A (zh) * 2016-11-30 2020-02-07 班塔姆制药有限责任公司 使用被取代的吡唑和吡咯化合物以及治疗过度增生性疾病的方法
CN110603254B (zh) * 2016-11-30 2024-04-12 班塔姆制药有限责任公司 被取代的吡唑化合物以及使用其治疗过度增生性疾病的方法
CN110950848A (zh) * 2018-09-27 2020-04-03 徐诺药业 新型氨基吡唑类衍生物的合成与应用
CN110950848B (zh) * 2018-09-27 2024-03-26 徐诺药业 新型氨基吡唑类衍生物的合成与应用
CN114867724A (zh) * 2019-05-31 2022-08-05 班塔姆制药有限责任公司 用于制备噻唑基吡唑甲酸及其中间体的方法
CN115515685A (zh) * 2020-03-03 2022-12-23 皮克医疗公司 Eif4e抑制剂及其用途

Also Published As

Publication number Publication date
MX2017015456A (es) 2018-11-29
JP6707630B2 (ja) 2020-06-10
US11602526B2 (en) 2023-03-14
US10537558B2 (en) 2020-01-21
EP3303332A1 (en) 2018-04-11
US20180311218A1 (en) 2018-11-01
US20200261424A1 (en) 2020-08-20
JP2018521119A (ja) 2018-08-02
IL255898A (en) 2018-01-31
WO2016196644A1 (en) 2016-12-08
BR112017025851A2 (pt) 2018-10-16
CA3025492A1 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
CN108349962A (zh) 取代的吡唑和吡咯化合物以及使用其用于抑制翻译起始和治疗与其相关的疾病和病症的方法
CN110769823A (zh) 使用被取代的吡唑和吡咯化合物以及治疗过度增生性疾病的方法
CN110372550B (zh) 芳基醚及其用途
EP3704106B1 (en) Alkene compounds as farnesoid x receptor modulators
DK2592934T3 (en) NOVEL dihydropyridin-2 (1H) -one compounds as S-NITROSOGLUTATHIONREDUKTASEINHIBITORER and neurokinin-3 receptor antagonists
CN110603254A (zh) 被取代的吡唑化合物以及使用其治疗过度增生性疾病的方法
EP3704107B1 (en) Multicyclic compounds as farnesoid x receptor modulators
CN101835752A (zh) 用于治疗癌症和银屑病的杂环酰胺
CN102119152A (zh) 有机化合物
KR102470130B1 (ko) 아폽토시스 억제제
TWI718146B (zh) 新穎的5-脂氧合酶啟動蛋白（ｆｌａｐ）抑制劑
CN105566311A (zh) 噁唑及异噁唑钙释放激活的钙调节剂
CN113727973B (zh) 可用作类法尼醇x受体调节剂的取代酰胺化合物
CN113677659B (zh) 可用作类法尼醇x受体调节剂的经取代的酰胺化合物
TWI881587B (zh) 類木瓜蛋白酶(PLpro)抑制劑
CN113677666A (zh) 作为类法尼醇x受体调节剂的经取代的双环化合物
AU2024312215A1 (en) Compositions and methods of use to treat 12-lipoxygenase (12-lox) mediated diseases
WO2024121709A1 (en) Papain-like protease (plpro) inhibitors
HK40106673A (zh) 取代哌啶化合物及其制备方法和应用
HK40106673B (zh) 取代哌啶化合物及其制备方法和应用
HK40117760A (zh) Rip1调节剂、其制备及用途
HK1200451B (en) Protein kinase inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180731